Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 10/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6632245 | 0.87 | ADAM17 (0.63) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL3969746 | 0.86 | ADAM17 (0.61) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL8353322 | 0.86 | ADAM17 (0.62) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL5887602 | 0.85 | ADAM17 (0.61) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL5887895 | 0.85 | ADAM17 (0.61) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL1366484 | 0.83 | ADAM17 (0.60) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL4053178 | 0.83 | ADAM17 (0.60) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL5041563 | 0.83 | ADAM17 (0.60) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL1364646 | 0.83 | ADAM17 (0.60) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL5036450 | 0.83 | ADAM17 (0.55) | ADAM17MMP13MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628974-A4 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7132432-B2 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1628974-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004108086-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108086-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254231-A1 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254231-A1 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, MMP3 | ADAM17 1/4885MMP13 12/4885MMP2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.